^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer undergoing checkpoint inhibitor therapy

Published date:
06/18/2021
Excerpt:
...metastatic urothelial cancer(mUCa)...Within a cohort of 72 patients with mUCa from five academic centers in Germany FGFR alterations, as well as FGFR1-4 mRNA expression levels in tumor samples from the primary tumor or metastatic sites...to examine the impact of different FGFR patterns on the DSS after CPI treatment. Low expression of FGFR2 mRNA alone, as well as the combination of either low FGFR2mRNA expression and FGFR3 gene alteration or high FGFR3mRNA expression (p=0.027), identified a subgroup of patients with unfavorable outcomes, comprising 40% of the total cohort. These patients showing overexpression of FGFR3 mRNA were found to have unfavorable DSS after CPI treatment.
DOI:
10.1016/j.urology.2021.05.055